Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect

Area of Science:

• Neuroscience
• Genetics
• Biochemistry

Background:

• Neuromuscular junctions (NMJs) are critical for muscle contraction, and their disorders, like congenital myasthenic syndromes (CMS), offer insights into synapse development.
• Understanding the genetic basis of hereditary neuromuscular transmission disorders is essential for elucidating fundamental synaptic processes.

Purpose of the Study:

• To identify the genetic cause of autosomal recessive congenital myasthenic syndromes (CMS).
• To investigate the role of the identified gene in neuromuscular junction development and function.

Main Methods:

• Genetic linkage analysis was employed to identify mutations in affected families.
• Gene orthologs were studied in zebrafish embryos to assess functional consequences.
• Biochemical pathways involving the identified enzyme were analyzed.

Main Results:

• Eighteen distinct biallelic mutations in the glutamine-fructose-6-phosphate transaminase 1 (GFPT1) gene were identified in 13 unrelated families with autosomal recessive CMS.
• Downregulation of the zebrafish gfpt1 ortholog resulted in abnormal muscle fiber morphology and impaired NMJ development.
• GFPT1 was confirmed as the rate-limiting enzyme in the hexosamine pathway, producing UDP-N-acetylglucosamine, crucial for protein glycosylation.

Conclusions:

• Mutations in GFPT1 are a significant cause of autosomal recessive congenital myasthenic syndromes.
• The hexosamine pathway and protein glycosylation are vital for proper neuromuscular junction development and function.
• These findings highlight the importance of glycobiology in synaptic function and disease.